230 related articles for article (PubMed ID: 31303271)
1. The novel small molecular BH3 mimetics SM3 and its regulation of cell apoptosis and autophagy.
Wang Y; Fan S; Li X; Xiaokaiti Y; Pan Y; Tie L; Li X
Biochem Biophys Res Commun; 2019 Sep; 517(1):15-22. PubMed ID: 31303271
[TBL] [Abstract][Full Text] [Related]
2. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
3. High-Throughput Screens To Identify Autophagy Inducers That Function by Disrupting Beclin 1/Bcl-2 Binding.
Chiang WC; Wei Y; Kuo YC; Wei S; Zhou A; Zou Z; Yehl J; Ranaghan MJ; Skepner A; Bittker JA; Perez JR; Posner BA; Levine B
ACS Chem Biol; 2018 Aug; 13(8):2247-2260. PubMed ID: 29878747
[TBL] [Abstract][Full Text] [Related]
4. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.
Hartman ML; Czyz M
Anticancer Agents Med Chem; 2012 Oct; 12(8):966-81. PubMed ID: 22263800
[TBL] [Abstract][Full Text] [Related]
5. The novel small molecule BH3 mimetic nobiletin synergizes with vorinostat to induce apoptosis and autophagy in small cell lung cancer.
Li YQ; Fan F; Wang YR; Li LY; Cao YJ; Gu SM; Liu SS; Zhang Y; Wang J; Tie L; Pan Y; Li HF; Li XJ
Biochem Pharmacol; 2023 Oct; 216():115807. PubMed ID: 37716621
[TBL] [Abstract][Full Text] [Related]
6. Autophagy inhibition enhances pan-Bcl-2 inhibitor AT-101-induced apoptosis in non-small cell lung cancer.
Mei H; Lin Z; Wang Y; Wu G; Song Y
Neoplasma; 2014; 61(2):186-92. PubMed ID: 24299314
[TBL] [Abstract][Full Text] [Related]
7. BH3 mimetics reveal the network properties of autophagy-regulatory signaling cascades.
Malik SA; Shen S; Mariño G; BenYounès A; Maiuri MC; Kroemer G
Autophagy; 2011 Aug; 7(8):914-6. PubMed ID: 21508685
[TBL] [Abstract][Full Text] [Related]
8. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
9. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L).
Maiuri MC; Criollo A; Tasdemir E; Vicencio JM; Tajeddine N; Hickman JA; Geneste O; Kroemer G
Autophagy; 2007; 3(4):374-6. PubMed ID: 17438366
[TBL] [Abstract][Full Text] [Related]
10. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
Suvarna V; Singh V; Murahari M
Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
[TBL] [Abstract][Full Text] [Related]
11. The Bcl-2-Beclin 1 interaction in (-)-gossypol-induced autophagy versus apoptosis in prostate cancer cells.
Lian J; Karnak D; Xu L
Autophagy; 2010 Nov; 6(8):1201-3. PubMed ID: 20930561
[TBL] [Abstract][Full Text] [Related]
12. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
Zhang L; Ramesh P; Steinmetz M; Medema JP
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
[TBL] [Abstract][Full Text] [Related]
13. Identification of inhibitors of Bcl-2 family protein-protein interaction by combining the BRET screening platform with virtual screening.
Park IS; Seo HR; Kim K; Lee H; Shum D; Choi I; Kim J
Biochem Biophys Res Commun; 2020 Jun; 527(3):709-715. PubMed ID: 32423828
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic inhibition of BCL-2 and related family members.
Levy MA; Claxton DF
Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
[TBL] [Abstract][Full Text] [Related]
16. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
17. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
18. The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma.
Arulananda S; Lee EF; Fairlie WD; John T
Expert Rev Anticancer Ther; 2021 Apr; 21(4):413-424. PubMed ID: 33238762
[No Abstract] [Full Text] [Related]
19. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.
Koss B; Ryan J; Budhraja A; Szarama K; Yang X; Bathina M; Cardone MH; Nikolovska-Coleska Z; Letai A; Opferman JT
Oncotarget; 2016 Mar; 7(10):11500-11. PubMed ID: 26862853
[TBL] [Abstract][Full Text] [Related]
20. Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment.
Abdul Rahman SF; Xiang Lian BS; Mohana-Kumaran N
Future Oncol; 2020 Oct; 16(28):2235-2249. PubMed ID: 32715755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
